Ticker LaunchReverse merger · Completed · XFOR
X4 Therapeutics, Inc.
Reverse merger with Arsanis, Inc.
X4 Therapeutics, Inc. merged into Arsanis, Inc., a Nasdaq-listed clinical-stage biopharmaceutical company, in a reverse merger that takes the private company public. The deal was announced on Nov 26, 2018 and closed on Mar 13, 2019. The combined company trades as X4 Pharmaceuticals, Inc. (XFOR) on Nasdaq.
X4 Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases. It became public through its merger with Arsanis and trades on Nasdaq under the symbol XFOR.
- Status
- Completed
- Private company
- X4 Therapeutics, Inc.
- Public company
- Arsanis, Inc.
- Public company business before
- Nasdaq-listed clinical-stage biopharmaceutical company
- Announced
- Nov 26, 2018
- Closed
- Mar 13, 2019
- Combined company
- X4 Pharmaceuticals, Inc. (XFOR)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Form 8-K (completion of acquisition) Mar 13, 2019
- Press release (Exhibit 99)
- All filings on EDGAR CIK 1501697
Other completed reverse mergers
- Immunic AG (German private company)into Vital Therapies, Inc. · Apr 12, 2019
- Gadsden Growth Properties, Inc.into FC Global Realty Incorporated · Apr 5, 2019
- PDS Biotechnology Corporationinto Edge Therapeutics, Inc. · Mar 15, 2019
- OWP Ventures, Inc.into Punto Group, Corp. (One World Pharma, Inc.) · Feb 21, 2019
- Lovego Holdings Limitedinto Quintec Corp (Love International Group) · Feb 11, 2019
- SCWorx Corp.into Alliance MMA, Inc. · Feb 1, 2019